Patents for A61P 35 - Antineoplastic agents (221,099)
06/2011
06/02/2011US20110130447 Production of hop extracts having oestrogenic and antiproliferative bioactivity
06/02/2011US20110130446 Injectable taxane pharmaceutical composition
06/02/2011US20110130437 Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
06/02/2011US20110130436 Caspase inhibitors and uses thereof
06/02/2011US20110130418 Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53
06/02/2011US20110130414 Novel fused thiazolo and oxazolo pyrimidinones
06/02/2011US20110130412 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
06/02/2011US20110130409 Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
06/02/2011US20110130406 Pyrazolo-pyridines as tyrosine kinase inhibitors
06/02/2011US20110130404 Quinoxalinedione derivatives
06/02/2011US20110130401 New chemical compounds
06/02/2011US20110130399 Phthalazine Derivatives with Angiogenesis Inhibiting Activity
06/02/2011US20110130398 Spiroindolinone pyrrolidines
06/02/2011US20110130396 Imidazothiadiazole derivatives
06/02/2011US20110130395 P13k isoform selective inhibitors
06/02/2011US20110130394 Pharmaceutical compounds
06/02/2011US20110130393 Inhibitors of janus kinases
06/02/2011US20110130391 Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
06/02/2011US20110130386 Dna-pk inhibitors
06/02/2011US20110130380 Heteroaryl Kinase Inhibitors
06/02/2011US20110130378 Ezetimibe process and composition
06/02/2011US20110130376 New no releasing steroids derivatives
06/02/2011US20110130374 Small Pyrimidine Derivatives and Methods of Use Thereof
06/02/2011US20110130368 Derivatives of 4- or 5-aminosalicylic acid
06/02/2011US20110130367 Combination Therapy for Treating Proliferative Diseases
06/02/2011US20110130363 Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
06/02/2011US20110130362 A2b adenosine receptor antagonists
06/02/2011US20110130361 Silicon derivatives as histone deacetylase inhibitors
06/02/2011US20110130359 Methods for preventing or reducing neurotoxicity associated with administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
06/02/2011US20110130358 Method for transdifferentiation of body tissues
06/02/2011US20110130354 Sulfated oligosaccharide derivatives
06/02/2011US20110130353 Highly purified antiendotoxin compound
06/02/2011US20110130344 Tight junction protein modulators and uses thereof
06/02/2011US20110130343 Immunity-inducing agent and method for detection of cancer
06/02/2011US20110130342 Peptide homing to brain tumors
06/02/2011US20110130341 Method and kit for detection of cancer, and therapeutic agent for cancer
06/02/2011US20110130340 Methods of identifying anti-cancer agents and uses thereof
06/02/2011US20110130327 Multi-Arm Amines and Uses Thereof
06/02/2011US20110130324 Methods for systematic control of protein stability
06/02/2011US20110129550 Cancer treatment method
06/02/2011US20110129549 Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
06/02/2011US20110129537 Functionalized metal-coated energy converting nanoparticles, methods for production thereof and methods for use
06/02/2011US20110129533 Porous drug matrices and methods of manufacture thereof
06/02/2011US20110129524 Therapeutic agent for cancer, and method for treatment of cancer
06/02/2011US20110129521 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
06/02/2011US20110129503 Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy
06/02/2011US20110129499 Dual delivery system for heterologous antigens
06/02/2011US20110129496 Use of mTOR Inhibitors to Enhance T Cell Immune Responses
06/02/2011US20110129483 Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
06/02/2011US20110129482 Polypeptide compounds for inhibiting angiogenesis and tumor growth
06/02/2011US20110129481 Antibody specifically binding to c-Met and methods of use
06/02/2011US20110129480 Anti-ferroportin 1 monoclonal antibodies and uses thereof
06/02/2011US20110129478 Pharmaceutical composition for treatment and prevention of cancer
06/02/2011US20110129474 Methods And Systems For Multi-Antibody Therapies
06/02/2011US20110129473 Vhnar anti-cytokine domains
06/02/2011US20110129471 Chronic lymphocytic leukemia cell line
06/02/2011US20110129470 Use of specifically engineered enzymes to enhance the efficacy of prodrugs
06/02/2011US20110129467 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
06/02/2011US20110129466 Methods of treating cancer by administering antibodies to cd200
06/02/2011US20110129464 Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
06/02/2011US20110129463 Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof
06/02/2011US20110129461 Mat II Beta Subunit RNAi and Therapeutic Methods Using Same
06/02/2011US20110129457 Variant hhip1 protein and methods and uses thereof
06/02/2011US20110129456 Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
06/02/2011US20110129455 Inhibitors of akt activity
06/02/2011US20110129448 Methods to mobilize progenitor/stem cells
06/02/2011US20110129447 Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy
06/02/2011US20110129446 Clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer
06/02/2011US20110129445 Combinations comprising methotrexate and dhodh inhibitors
06/02/2011US20110129440 Heterocyclic Urea and Thiourea Derivatives and Methods of Use Thereof
06/02/2011US20110129423 Anticancer compounds and screening method
06/02/2011US20110129422 Viscous Terpolymers as Drug Delivery Platform
06/02/2011US20110129421 Matrix metalloprotease targeting nucleic acids
06/02/2011US20110129418 Brain Tumor Targeting Peptides and Methods
06/02/2011US20110129417 Administrable compositions
06/02/2011US20110129416 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
06/02/2011US20110129412 Antibodies Directed to CD20 and Uses Thereof
06/01/2011EP2327775A2 Therapy for alpha-galactosidase a deficiency
06/01/2011EP2327705A1 Podophyllotoxins as antiproliferative agents
06/01/2011EP2327697A1 The salts of n-ý4-(1-cyanocyclopentyl)phenyl¨-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
06/01/2011EP2327690A1 Tricyclic compound
06/01/2011EP2327451A2 Method for detecting and inhibiting angiogenesis
06/01/2011EP2327418A1 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from other viruses
06/01/2011EP2327413A1 Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
06/01/2011EP2327409A1 Tetracycline compound having target therapeutic activities
06/01/2011EP2327408A1 Tetracyclic cyclic gmp-specific phosphodiesterase inhibitors for the treatment of benign prostatic hypertrophy
06/01/2011EP2326718A1 Inhbb epitope peptides and vaccines containing the same
06/01/2011EP2326668A1 Anti-il-12/il-23 antibodies
06/01/2011EP2326653A1 New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents
06/01/2011EP2326649A1 Novel pyrrolo ý2,3-a¨carbazoles and use thereof as pim kinase inhibitors
06/01/2011EP2326647A1 6-substituted 2-(benzimidazolyl)purine and purinone derivatives and 6-substituted 2-(imidazoioý4,5- c¨pyridinyl)purine and purinone derivatives for immunosuppression
06/01/2011EP2326646A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
06/01/2011EP2326645A1 Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it
06/01/2011EP2326641A2 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
06/01/2011EP2326636A2 Pyrazole carboxamide inhibitors of factor xa
06/01/2011EP2326631A2 Mif modulators
06/01/2011EP2326622A1 Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
06/01/2011EP2326350A2 Methods for killing psma-expressing, taxane-resistant cancer cells
06/01/2011EP2326329A1 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
06/01/2011EP2326320A1 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas